Michal Tomcik

Charles University

Dr. Michal Tomcik is associate professor at 1st Faculty of Medicine, Charles University, Prague, Czech Republic. From 2014 till 2018 he was assistant professor at 1st Faculty of Medicine, Charles University, Prague. Since 2013 he has been a tutor of pre-graduate (4) and postgraduate (4) students at Charles University, Prague, since 2008 he has been a translator at the Czech Society of Rheumatology and since 2007 he has been a rheumatologist at Institute of Rheumatology in Prague. His licensure includes Board examination in rheumatology from 2015. Dr. Michal Tomcik\'s education includes: 2007 – 2014 1st Faculty of Medicine, Charles University, Prague, PhD. Thesis title: „The role of new pro-inflammatory and/or pro-fibrotic molecules in the pathogenesis of systemic sclerosis' and 2000 – 2007 1st Faculty of Medicine, Charles University, Prague, general medicine, MD. His professional exchange abroad experience includes a 07/2009 – 11/2011 EULAR Scientific Training in the Department for Internal Medicine 3 and Institute for Clinical Immunology Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany where he was a postgraduate research fellow.

1books edited

4chapters authored

Latest work with IntechOpen by Michal Tomcik

Systemic sclerosis (scleroderma) is an incurable connective tissue disease of unknown etiology. Three key processes play a pivotal role in the pathogenesis: immune dysregulation and inflammation, endothelial injury and vasculopathy, and fibrosis. Tissue fibrosis is the dominant and characteristic feature that affects the skin and visceral organs. Life expectancy of scleroderma patients has improved over recent years, mainly because of better treatment of organ involvement and complications; however, no curative disease-modifying therapies exist to date. This book aims to provide students, trainees, rheumatologists, and other specialists interested in this disease with a comprehensive overview of novel pathogenetic mechanisms, management approaches, and therapeutic targets of several major vascular and fibrotic manifestations, and is useful insight into a number of usually neglected aspects of scleroderma.

Go to the book